Robust inflammatory breast cancer gene signature using nonparametric random forest analysis
Source check: Source checked. Not independent scientific confirmation.
Finding: Random-forest analysis of expression datasets derived the 59-gene G59 signature for inflammatory breast cancer. It distinguished untreated inflammatory-breast-cancer samples in independent datasets, but did not classify primarily post-treatment samples reliably; the signature remains a candidate molecular classifier.
Technology: Nonparametric random forest feature analysis and G59 gene-signature classification
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
- AI contribution
- Random forest analysis prioritized genes and derived the 59-gene signature distinguishing inflammatory breast cancer from comparison samples.
- Test and result
- G59 classified 45/45 discovery/validation samples and 60/61 samples in an independent pretreatment dataset; TCGA testing yielded 1.6% IBC-like classifications.
- Limitation / still unknown
- Performance did not transfer reliably to primarily post-treatment samples; this is retrospective expression-data validation, not prospective diagnostic use.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://link.springer.com/article/10.1186/s13058-021-01467-y
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 22 Nov 2026. Review scope: Publisher full-text Methods and Results; date and exact-result catalog comparison checked..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.